Milestone Pharmaceuticals (MIST) EBT Margin (2021 - 2022)
Milestone Pharmaceuticals' (MIST) quarterly EBT Margin came in at 970.4% in Q3 2022, down 19003.9% quarter-over-quarter from 5.13% in Q2 2021.
Powered by 
Analysis
Milestone Pharmaceuticals (MIST) EBT Margin (2021 - 2022) Analysis & Trends
Milestone Pharmaceuticals (MIST) has reported EBT Margin for 2 consecutive years, with 970.4% the latest figure, recorded in Q3 2022.
- For the quarter ending Q3 2022, EBT Margin changed N/A year-over-year to 970.4%; the trailing twelve-month figure through Sep 2022 stood at 377.65% (changed N/A YoY), and the FY2021 full-year result was 285.69%, changed N/A from the prior year.
- EBT Margin declined to 970.4% in Q3 2022 per MIST's latest filing, from 5.13% in the prior quarter.
- Across five years, EBT Margin topped out at 5.13% in Q2 2021 and bottomed at 970.4% in Q3 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 27.53% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -131.41% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 41.75% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 35.61% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 35.78% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -528.97% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 13.77% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 4.84% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -20,427.46% |
| 10 | Milestone Pharmaceuticals | 146.32 Mn | -25.18 Mn | - | - |